

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AB Science (masitinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Beacon • Brain and Spine Foundation • Brain Charity • Gene People • Genetic Alliance UK • Marie Curie • Motor Neurone Disease Association • My Name's5 Doddie Foundation • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association of Neuroscience Nurses • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • British Thoracic Society • Chartered Society of Physiotherapy • Institute of Neurology • Institute of Psychiatry National Neuroscience Advisory Group • Primary Care and Community Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Occupational Therapists • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AAH Pharmaceuticals (Riluzole) • Alliance Healthcare (Riluzole) • Glenmark Pharmaceuticals Europe (riluzole) • Martindale Pharma (riluzole) • Medihealth northern Ltd (riluzole) • Ranbaxy UK (riluzole) • Sanofi (riluzole) • Sigma (riluzole) • Sun Pharmaceuticals Europe (riluzole) • Zambon UK (riluzole)

Provisional stakeholder list for the evaluation of masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

Issue date: January 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal College of Psychiatrists • Royal College of Speech and Language Therapists • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • National Hospital for Neurology and Neurosurgery • Sheffield MND Care Centre • King’s MND Care and Research Centre, King’s College Hospital • The Walton Centre • NHS England 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Cochrane Airways group • Cochrane Cystic Fibrosis and Genetic Disorders Group • Cochrane Movement Disorders Group • Cochrane UK • Genomics England • Institute of Neurology • MRC Clinical Trials Unit • National Institute for Health Research • Oxford Motor Neuron Disease Centre • UCL Institute of Neurology • UK MND Research Institute <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.